Trial 10M-17-4


A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Immunotherapy
Randomized: Yes
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Lusine Raddatz, D.M., Gina Tse, Coordinator, Kristy Sartor Massopust, Coordinator, Noureddine Miloud, D.M., Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Janelle Luevano, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.